S&P 500
7,764.60
+0.10%
Dow Jones
54,006.40
-0.05%
Nasdaq 100
29,816.40
+0.29%
Russell 2000
3,031.82
-0.10%
FTSE 100
10,868.60
-0.30%
Nikkei 225
67,106.30
+1.22%
Charles River Laboratories

Charles River Laboratories (CRL) Q2 2026 Earnings

Reported Aug 5, 2026 at 7:15 AM ET · SEC Source

Q2 26 EPS

$3.02

BEAT +10.65%

Est. $2.73

Q2 26 Revenue

$1.00B

BEAT +2.75%

Est. $977.2M

vs S&P Since Q2 26

+13.8%

BEATING MARKET

CRL +14.3% vs S&P +0.5%

Market Reaction

Did CRL Beat Earnings? Q2 2026 Results

Charles River Laboratories delivered a stronger-than-expected second quarter, posting non-GAAP diluted EPS of $3.02 against the $2.73 consensus estimate, a 10.65% beat that marked the company's fifth consecutive quarter of exceeding EPS expectations.… Read more Charles River Laboratories delivered a stronger-than-expected second quarter, posting non-GAAP diluted EPS of $3.02 against the $2.73 consensus estimate, a 10.65% beat that marked the company's fifth consecutive quarter of exceeding EPS expectations. Revenue of $1.00 billion topped the $977.20 million consensus by 2.75%, though it declined 2.7% year-over-year, a drop largely attributable to the completed divestitures of the CDMO and Cell Solutions businesses rather than underlying demand erosion. The more telling signal came from the DSA segment, where the net book-to-bill ratio reached its highest level in nearly four years, with demand improvement described as broad-based across both large biopharmaceutical and small-to-mid-sized biotech clients. That momentum gave management enough confidence to raise full-year guidance, lifting organic revenue growth expectations to 0.0%-1.0% and increasing non-GAAP EPS guidance to $11.15-$11.45, a $0.25 midpoint improvement, even as GAAP EPS guidance was trimmed to $3.05-$3.35 to reflect divestiture-related losses recorded in the quarter.

Key Takeaways

  • • DSA segment recorded highest net book-to-bill in nearly four years with broad-based improvement across global biopharmaceutical and small/mid-sized biotech clients
  • • Organic revenue growth of 0.1% was the highest since Q3 2023
  • • Manufacturing segment organic revenue increased 1.3% driven by higher Microbial Solutions revenue
  • • Non-GAAP operating margin increased 420 basis points sequentially to 20.5%
  • • Deferred compensation plan investment gains provided $0.19 per share benefit

CRL Forward Guidance & Outlook

Charles River raised its 2026 guidance. Reported revenue growth is now expected at (3.5)% to (2.5)%, with organic revenue growth of 0.0% to 1.0% (up 150 basis points at midpoint). Non-GAAP EPS guidance increased to $11.15–$11.45 (up $0.25 at midpoint), primarily driven by improving demand trends in the DSA segment and better-than-expected Manufacturing segment performance. GAAP EPS guidance was lowered to $3.05–$3.35 due to the net loss on divestitures. The company expects Q2 deferred compensation plan investment gains to be largely offset by a higher tax rate for the full year, with negligible net impact to non-GAAP EPS.

24/7 Wall St

CRL YoY Financials

Q2 2026 vs Q2 2025, source: SEC Filings

24/7 Wall St

CRL Revenue by Segment

With YoY comparisons, source: SEC Filings

Q1 25 Q2 26

“We made excellent progress in the second quarter on the execution of our Pathway to Purpose strategy. We are actively evaluating opportunities to modernize the Company and drive greater efficiency, to strengthen our leading drug development portfolio centered on regulated testing, and to further enhance our growth profile. We are focused on continuing to move forward on achieving our strategic initiatives and financial goals, which will strengthen our foundation and underpin our future success.”

— Birgit Girshick, Q2 2026 Earnings Press Release

Back to CRL Stock Page